Table 1. Clinico-pathological characteristics of breast cancer patients in relation to macrophage count (CD68 expression).
Distributions of tumour macrophage number (CD68 expression) categorisations according to clinical-pathological and molecular parameters (percentages in parenthesis). Macrophage count was divided into low and high by the median value. High level of macrophage infiltration was associated with higher tumour grade and lymph node metastasis.
| Macrophage (CD68) n=129 | p-value | ||
|---|---|---|---|
| Low | High | ||
| Number of patients | 68 (52.7%)%) | 61 (47.3%) | |
| Age (years) | |||
| median (range) | 66.5 (35-91) | 64.0 (34-97) | 0.8541 |
| Tumour size | |||
| ≤20mm | 39 (59.1%) | 27 (40.9%) | 0.1603 |
| >20mm | 29 (46.0%) | 34 (54.0%) | |
| Grade | |||
| I | 11 (57.9%) | 8 (42.1%) | 0.0232 |
| II | 38 (63.3%) | 22 (36.7%) | |
| III | 19 (38.0%) | 31 (62.0%) | |
| Lymph node status | |||
| negative | 41 (61.2%) | 26 (38.8%) | 0.0443 |
| positive | 22(42.3%) | 30(57.7%) | |
| Oestrogen receptor status | |||
| negative | 5 (31.2%) | 11 (68.8%) | 0.1063 |
| positive | 63 (55.8%) | 50 (44.2%) | |
| Progesterone receptor status | |||
| negative | 18 (46.2%) | 21 (53.8%) | 0.3443 |
| positive | 50 (55.6%) | 40 (44.4%) | |
| HER2 status | |||
| negative | 62 (53.0%) | 55 (47.0%) | 0.7353 |
| positive | 4 (44.4%) | 5 (55.6%) | |
| Ki67 | |||
| ≤10% | 1 (16.7%) | 5 (83.3%) | 1.0002 |
| 11-25% | 27 (57.4%) | 20 (42.6%) | |
| >25% | 28 (48.3%) | 30 (51.7%) | |
1
Kruskel Wallis
2
Spearman's Rho
3
Fisher's Exact.